From: Is exposure in vivo cost-effective for chronic low back pain? A trial-based economic evaluation
 | Mean (SD) | Mean difference (95 % CI) | |
---|---|---|---|
 | GA (n = 31) | EXP (n = 31) | EXP versus GA |
QBPDSb | 40.42 (22.34) | 38.19 (20.84) | −2.23 (-13.20 to 8.75) |
Utility (SF36)b | 0.68 (0.14) | 0.66 (0.14) | −0.15 (-0.08 to 0.05) |
QALYb | 0.82 (0.12) | 0.83 (0.13) | 0.01 (-0.6 to 0.07) |
Treatment costs | 1,969.39 (0) | 2,166.84 (0) | 197.45 |
Health care costsa | 1,841.72 (595.12) | 1,011.67 (220.68) | −830 (-2,209 to 247) |
P & F costsa | 5,347.25 (1229.70) | 5,012.60 (1302.51) | −335 (-3,708 to 3,320) |
Productivity lossa | 4,002.20 (1484.43) | 2,502.57 (1055.98) | −1,500 (-4,987 to 1,907) |
Total costs a | 13,477.71 (2450.28) | 10,843.50 (1747.89) | −2,643 (-8,535 to 3,058) |